Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: A phase I/II pilot study

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 4, 2011, Pages 1005-1016

  Ratto, G B ^a   Costa, R ^b   Maineri, P ^c   Alloisio, A ^a   Piras, M T ^a   D'Agostino, A ^d   Tripodi, G ^d   Rivabella, L ^d   Dozin, B ^a   Bruzzi, P ^a   Melioli, Giovanni ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UOS Antonio e Biagio e C Arrigo Hospital   (Italy)

^c SANTA CORONA HOSPITAL   (Italy)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

Neo adjuvant chemotherapy; Neo adjuvant immunotherapy; Non small cell lung cancer; Surgery; Survival

Indexed keywords

CISPLATIN; GEMCITABINE; LIQUID NITROGEN; RECOMBINANT INTERLEUKIN 2; CD4 ANTIGEN; CD8 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL ISOLATION; CELL THERAPY; CELL VIABILITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FEVER; HUMAN; HUMAN CELL; LEUKAPHERESIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG POTENCY; FEASIBILITY STUDY; FOLLOW UP; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LYMPH NODE DISSECTION; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84856577648     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400418     Document Type: Article

References (17)

1. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer 1996; 78:244-51. (Pubitemid 26234566)
2. Ratto GB, Cafferata MA, Scolaro T, Bruzzi P, Alloisio A, Costa R, Spessa E, Semino C, Melioli G. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 2000; 23:161-67. (Pubitemid 30079837)
3. Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J Biol Regul Homeost Agents. 1993; 7:121-25. (Pubitemid 24118977)
4. Kimura H. Post-surgical adjuvant chemoimmunotherapy by activated autologous killer cells and dendritic cells from regional lymph nodes of the lung cancer patients. Lung Cancer 2005; 49:S79.
5. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23:6674-81. (Pubitemid 46190262)
6. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase HB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thorac Oncol 2007; 2:S332-33.
7. Vansteenkiste J, Zielinksi M, Linder A, et al. Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study: B1-05. J Thorac Oncol 2007; 2:S334-35.
8. Skitzki J, Craig RA, Okuyama R, Knibbs RN, McDonagh K, Chang AE, Stoolman LM. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 2004; 64:2183-91. (Pubitemid 38339471)
9. Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1990; 99:48-53 (Pubitemid 20041513)
10. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Watanabe S, Tatsuzawa Y, Iwa T, Suzuki M, Takashima T. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 1991; 51:253-61
11. Melioli G, Ratto G, Guastella M, et al. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer 1994; 30:97-102. (Pubitemid 24058098)
12. Del Mastro L, Venturini M, Viscoli C, et al. Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. Ann Oncol 2001; 12:505-8. (Pubitemid 32472106)
13. Robinson LA, Wagner H Jr, Ruckdeschel JC; American College of Chest Physicians. Treatment of stage IIIA non-small cell lung cancer. Chest 2003; 123:202-20S.
14. nd edition). Chest 2007; 132:243-265S.
15. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009; 6:224-32.
16. Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago M, Brera G. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents 2006; 20:29-35.
17. Imai H, Sunaga N, Shimizu Y, et al. Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol 2010; 23:153-64